See more : St. James’s Place plc (STJ.L) Income Statement Analysis – Financial Results
Complete financial analysis of Cellectis S.A. (CLLS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cellectis S.A., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Shihlin Paper Corporation (1903.TW) Income Statement Analysis – Financial Results
- DVL, Inc. (DVLN) Income Statement Analysis – Financial Results
- Anhui Zhongyuan New Materials Co., Ltd. (603527.SS) Income Statement Analysis – Financial Results
- Chemcrux Enterprises Limited (CHEMCRUX.BO) Income Statement Analysis – Financial Results
- China Solar & Clean Energy Solutions, Inc. (CSOL) Income Statement Analysis – Financial Results
Cellectis S.A. (CLLS)
About Cellectis S.A.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 755.00K | 19.17M | 73.95M | 73.95M | 15.19M | 12.73M | 25.19M | 42.58M | 55.04M | 26.30M | 22.82M | 27.81M | 20.73M | 20.98M | 17.32M | 14.77M | 4.10M |
| Cost of Revenue | 737.00K | 1.77M | 36.28M | 36.28M | 11.39M | 2.74M | 2.62M | 1.69M | 2.71M | 3.69M | 847.86K | 2.03M | 3.26M | 1.92M | 2.33M | 1.54M | 1.48M |
| Gross Profit | 18.00K | 17.40M | 37.67M | 37.67M | 3.80M | 9.99M | 22.57M | 40.90M | 52.34M | 22.61M | 21.97M | 25.78M | 17.47M | 19.06M | 14.99M | 13.23M | 2.62M |
| Gross Profit Ratio | 2.38% | 90.76% | 50.95% | 50.95% | 25.00% | 78.49% | 89.60% | 96.04% | 95.08% | 85.97% | 96.28% | 92.70% | 84.27% | 90.84% | 86.57% | 89.56% | 63.99% |
| Research & Development | 87.65M | 97.50M | 86.95M | 86.95M | 92.04M | 76.57M | 79.23M | 74.56M | 57.30M | 17.52M | 34.44M | 25.10M | 15.95M | 16.37M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 16.81M | 17.49M | 37.87M | 44.20M | 43.02M | 47.25M | 44.75M | 41.26M | 29.78M | 15.95M | 30.49M | 0.00 | 0.00 | 0.00 | 7.97M | 5.70M | 4.28M |
| Selling & Marketing | 0.00 | 3.11M | 6.33M | 1.66M | 11.43M | 16.69M | 9.14M | 8.41M | 6.67M | 6.57M | 18.14M | 0.00 | 0.00 | 17.90M | 0.00 | 0.00 | 0.00 |
| SG&A | 16.81M | 17.49M | 44.20M | 44.20M | 43.02M | 47.25M | 44.75M | 41.26M | 29.78M | 15.95M | 30.49M | 25.83M | 26.69M | 17.90M | 7.97M | 5.70M | 4.28M |
| Other Expenses | -7.14M | -7.93M | -8.04M | -8.04M | -7.71M | -25.42M | -17.90M | -19.38M | -10.88M | -11.05M | -15.95M | 995.85K | 142.57K | 35.91K | 19.54M | 12.32M | 4.37K |
| Operating Expenses | 97.32M | 107.07M | 123.11M | 123.11M | 127.35M | 115.08M | 115.22M | 104.86M | 82.87M | 28.98M | 67.13M | 51.92M | 42.78M | 34.31M | 27.51M | 18.03M | 10.41M |
| Cost & Expenses | 98.06M | 108.84M | 159.39M | 159.39M | 138.74M | 117.82M | 117.84M | 106.54M | 85.57M | 32.68M | 67.97M | 53.95M | 46.04M | 36.23M | 29.84M | 19.57M | 11.88M |
| Interest Income | 3.61M | 1.12M | 736.00K | 1.95M | 8.34M | 16.76M | 1.97M | 44.17K | 8.25M | 384.26K | 437.74K | 477.82K | 794.50K | 645.03K | 1.79M | 1.13M | 835.44K |
| Interest Expense | 6.43M | 3.79M | 5.34M | 12.05M | 2.61M | 46.00K | 4.00K | 6.31K | 22.96K | 195.78K | 407.36K | 2.32M | 632.49K | 203.48K | 8.60K | 13.92K | 29.16K |
| Depreciation & Amortization | 18.52M | 18.44M | 14.16M | 9.82M | 6.88M | 2.38M | 3.37M | 2.21M | 1.91M | 1.67M | 45.93M | 2.42M | 804.87K | 1.58M | 368.22K | 400.92K | 852.93K |
| EBITDA | -92.64M | -76.38M | -86.46M | -34.68M | -105.09M | -93.79M | -108.08M | -65.32M | -26.21M | 370.08K | 1.17M | -26.14M | -25.31M | -12.98M | -12.25M | -3.36M | -5.99M |
| EBITDA Ratio | -12,269.67% | -467.72% | -115.54% | -115.54% | -813.38% | -825.47% | -367.83% | -150.20% | -52.00% | -16.86% | 5.13% | -93.98% | -118.21% | -61.87% | -59.13% | -21.56% | -148.45% |
| Operating Income | -106.63M | -89.67M | -85.44M | -85.44M | -123.55M | -105.09M | -92.65M | -63.96M | -30.53M | -6.38M | -80.62M | -26.14M | -25.31M | -15.25M | -13.50M | -4.80M | -7.78M |
| Operating Income Ratio | -14,122.65% | -467.72% | -115.54% | -115.54% | -813.38% | -825.47% | -367.83% | -150.20% | -55.46% | -24.25% | -353.35% | -93.98% | -122.09% | -72.68% | -77.92% | -32.48% | -189.73% |
| Total Other Income/Expenses | -16.42M | -8.94M | 6.73M | -12.05M | 8.34M | 16.76M | -11.03M | 47.00K | 8.38M | 8.63M | -3.99M | -1.90M | 172.38K | 486.77K | 812.28K | 1.10M | 810.65K |
| Income Before Tax | -123.05M | -98.60M | -97.48M | -97.48M | -115.21M | -88.33M | -103.68M | -63.92M | -22.27M | 2.25M | -81.09M | -27.87M | -25.14M | -14.76M | -11.72M | -3.68M | -6.97M |
| Income Before Tax Ratio | -16,297.48% | -514.32% | -131.82% | -131.82% | -758.47% | -693.84% | -411.63% | -150.09% | -40.47% | 8.56% | -355.39% | -100.21% | -121.26% | -70.36% | -67.66% | -24.94% | -169.96% |
| Income Tax Expense | -6.21M | 87.00K | -11.20M | -24.91M | -24.53M | 16.81M | -13.20M | -1.54M | -926.03K | 2.42M | 4.68M | 1.58M | 5.76M | -4.04M | -6.20M | -3.87M | -2.61M |
| Net Income | -101.06M | -98.69M | -86.28M | -72.57M | -90.69M | -78.69M | -99.37M | -63.92M | -22.46M | 24.32K | -84.28M | -29.45M | -30.90M | -10.72M | -5.52M | 185.15K | -4.36M |
| Net Income Ratio | -13,385.30% | -514.78% | -116.68% | -98.14% | -597.01% | -618.12% | -394.51% | -150.10% | -40.81% | 0.09% | -369.38% | -105.89% | -149.05% | -51.11% | -31.87% | 1.25% | -106.22% |
| EPS | -1.77 | -2.17 | -1.93 | -1.71 | -2.14 | -1.93 | -2.78 | -1.81 | -0.66 | 0.00 | -4.08 | -1.48 | -2.19 | -0.76 | -0.39 | 0.01 | -0.31 |
| EPS Diluted | -1.77 | -2.17 | -1.93 | -1.71 | -2.14 | -1.93 | -2.78 | -1.78 | -0.65 | 0.00 | -4.08 | -1.48 | -2.19 | -0.76 | -0.39 | 0.01 | -0.31 |
| Weighted Avg Shares Out | 57.01M | 45.55M | 44.82M | 42.50M | 42.44M | 40.77M | 35.69M | 35.29M | 34.15M | 26.07M | 20.65M | 19.94M | 14.13M | 14.13M | 14.13M | 14.13M | 14.13M |
| Weighted Avg Shares Out (Dil) | 57.01M | 45.55M | 44.82M | 42.50M | 42.44M | 40.77M | 35.69M | 35.81M | 34.52M | 26.19M | 20.65M | 19.94M | 14.13M | 14.13M | 14.13M | 14.13M | 14.13M |
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at...
Cellectis' Shareholders Meeting to be Held on December 22, 2023
NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold a general meeting on...
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) today anounced that, following the consultation of its works council, it has now signed a binding Subsequent Investment Agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) regarding the...
Cellectis SA (CLLS) Q3 2023 Earnings Call Transcript
Cellectis SA (NASDAQ:CLLS ) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Co-founder, CEO& Director Mark Frattini - Chief Medical Officer Bing Wang - CFO Conference...
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
• Strategic Collaboration and Investment Agreements signed with AstraZeneca Updated results of the Phase I BALLI-01 Trial evaluating UCART22 in r/r B-cell ALL and preliminary results of the Phase I NATHALI-01 Trial evaluating UCART20x22 in r/r B-cell NHL to be...
Cellectis: End Of 2023 Data Readouts To Boost CAR-T Prospects
Preliminary data from two early-stage studies are going to be shown at the ASH 2023 conference, showcasing its cell therapy candidates for non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia. The company recently entered into a collaboration agreement with AstraZeneca, receiving...
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that preliminary results of the...
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results...
5 Most Active Penny Stocks Today & Why They're Moving Now
Penny stocks are the wild west of the stock market. Fast-paced, unpredictable, and laden with potential treasures.
Why Is Cellectis (CLLS) Stock Up 175% Today?
Cellectis (NASDAQ: CLLS ) stock is taking off on Wednesday after the company announced an investment from AstraZeneca (NASDAQ: AZN ). Cellectis and AstraZeneca have signed a strategic collaboration agreement that will see the latter investing $245 million into the former.
Source: https://incomestatements.info
Category: Stock Reports